HDACi exert their anti-cancer effects through several mechanisms. By inhibiting HDACs, they can lead to the accumulation of acetylated histones, causing chromatin relaxation and the reactivation of tumor suppressor genes. This can trigger cell cycle arrest, differentiation, and apoptosis in cancer cells. Additionally, HDACi can affect non-histone proteins, further influencing cellular processes such as DNA repair, immune response, and cell adhesion. These multifaceted actions make HDACi a promising therapeutic option in oncology.
